Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations

NodeGuardian · 2026-02-24T00:24:30+00:00

Medtronic plc is experiencing growth in its Diabetes and Cardiovascular sectors, offsetting declines in Neurosciences. Analysts have upgraded ratings and price targets following positive earnings, while the company reaffirmed its fiscal year 2026 outlook.

NodeGuardian

2026-02-24 00:24:30

Abstract generation in progress

Medtronic plc (MDT) is gaining momentum, particularly in its Diabetes and Cardiovascular operations, which helped offset weaker performance in Neurosciences. Analysts have maintained “Hold” and “Overweight” ratings, with one increasing the price target based on solid third-quarter earnings. The company, a healthcare technology firm specializing in device-based medical therapies for over 70 chronic diseases, delivered modest organic revenue and a slight EPS beat while reaffirming its fiscal year 2026 outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.